Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 03 2025 - 12:55PM
UK Regulatory
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare
Conference
Media Release
COPENHAGEN, Denmark; January 03, 2025
Genmab A/S (Nasdaq:
GMAB) announced today
that its CEO, Jan van de Winkel, Ph.D., will present a company
update at the
43rd
Annual J.P. Morgan Healthcare Conference
in San Francisco at
3:00 PM PST /
6:00 PM EST on January
14,
2025,
12:00 AM CET on
January 15, 2025. The live and archived
webcast of the presentation will be available on Genmab’s website
at https://ir.genmab.com/events-presentations.
About Genmab
Genmab is an international biotechnology company with a core
purpose of guiding its unstoppable team to strive toward improving
the lives of patients with innovative and differentiated antibody
therapeutics. For more than 25 years, its passionate, innovative
and collaborative team has invented next-generation antibody
technology platforms and leveraged translational, quantitative and
data sciences, resulting in a proprietary pipeline including
bispecific T-cell engagers, antibody-drug conjugates,
next-generation immune checkpoint modulators and effector
function-enhanced antibodies. By 2030, Genmab’s vision is to
transform the lives of people with cancer and other serious
diseases with knock-your-socks-off (KYSO) antibody
medicines®.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark, with international presence across North America, Europe
and Asia Pacific. For more information, please visit Genmab.com and
follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Media Release contains forward looking statements. The
words “believe,” “expect,” “anticipate,” “intend” and “plan” and
similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors
included in Genmab’s most recent Annual Report on Form 20-F and
other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at
www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Media
Release nor to confirm such statements to reflect subsequent events
or circumstances after the date made or in relation to actual
results, unless required by law.
Genmab A/S and/or its subsidiaries own the following
trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination
with the Y-shaped Genmab logo®;
HuMax®;
DuoBody®;
HexaBody®;
DuoHexaBody®,
HexElect® and
KYSO®.
Media Release no. i01
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
Genmab AS (TG:GE9)
Historical Stock Chart
From Dec 2024 to Jan 2025
Genmab AS (TG:GE9)
Historical Stock Chart
From Jan 2024 to Jan 2025
